Xbrane Biopharma Q2 2024: Initial take – stronger sales but higher costs - Redeye

Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher than estimated. However, the cost base and cash burn also surpassed expectations, resulting in a weaker EBIT than anticipated.

Länk till analysen i sin helhet: https://www.redeye.se/research/1035523/xbrane-biopharma-q2-2024-initial-take-stronger-sales-but-higher-costs?utm_source=finwire&utm_medium=RSS